{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 95,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "sparse",
  "nDataPoints": 12,
  "notes": "The slide highlights Mind Medicine (MindMed) Inc. with a red highlight, suggesting it is the primary target of the activist campaign.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/55",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.047,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source Refinitiv. See [20]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6d7307d-b031-4484-9d07-6be3656109a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.52,
        "w": 0.604,
        "x": 0.198,
        "y": 0.258
      },
      "kind": "table",
      "text": "Company, 2022 Average Non-Executive Director Compensation, 2022 Share Price Decline; Mind Medicine (MindMed) Inc., $688,191, -89%; Relmada Therapeutics Inc., $535,987, -84%; Compass Pathways Plc., $170,968, -64%; ATAI Life Sciences NV, $211,924, -67%; Numinus Wellness Inc., $150,198, -70%; Seelos Therapeutics Inc., $99,478, -56%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78f24634-7238-44d6-84ad-cb4d38037912",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.047,
        "y": 0.058
      },
      "kind": "title",
      "text": "Director Over-Compensation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1702b90d-8805-47c8-bd07-df8d2f6f62d0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 60,
      "from": 15,
      "beatId": "46c295b3-1c69-4f4e-b465-df8201aa88d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problems by highlighting the company's lack of accountability, excessive executive compensation, and dilutive financing approach.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}